News | February 02, 2026
Strides posts record Q3 EBITDA of Rs. 235.9 crore, operational PAT Up 39% YoY
Profitability metrics showed a sharper upward trend. Gross margin expanded 280 basis points to 61.2%
Profitability metrics showed a sharper upward trend. Gross margin expanded 280 basis points to 61.2%
These observations are procedural in nature and the company does not anticipate any impact on supply of its commercial products
Medroxyprogesterone acetate-SC is a three-month contraceptive that can be administered by healthcare workers or self-injected after appropriate training
Kenox to provide formulation and development expertise in orally inhaled and nasal drug products
For the full year FY25, net profit soared 12x to Rs 345 crore
Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base
Amexel aims to generate revenue through facilitation services and a profit-sharing model linked to the commercialization of products
Sarat Kumar has been appointed as CFO of the company and also designated as Key Managerial Personnel with effect from February 21, 2025
EBITDA grew 46.9% YoY to Rs. 210.3 crore with EBITDA margin at 18.2%, grew 401 bps YoY and the reported PAT at Rs. 90 crore
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
Subscribe To Our Newsletter & Stay Updated
